Edgewise Therapeutics

Boulder, Colorado-based Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for severe, rare muscle disorders for which there is a significant unmet medical need. This urgency drives Edgewise to evolve disease knowledge to create novel precision medicines for rare diseases caused by muscle dysfunction.

Though rare, muscular disorders such as Duchenne muscular dystrophy and Becker muscular dystrophy impact an estimated 20,000 patients in the United States, the effects of these diseases are often debilitating for patients. Edgewise has developed a pipeline of precision medicine candidates to target specific muscle proteins and modulators to address a broad array of genetic muscle disorders using a proprietary drug discovery platform.

Edgewise's vision is to improve the lives of patients and families suffering from these muscular disorders by building the world's leading muscle-focused, precision medicine company. Before its recent initial public offering, the company raised $160.7 million from leading institutional investors. Edgewise's lead product is currently under evaluation in Phase 1 clinical trials. The company intends to advance two other drug candidates into clinical development.

Edgewise recently expanded its operations to Portland, Oregon, where it established a satellite office with the Portland State Business Accelerator.